TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9813513

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion during rewarming stage of hypothermic CPB
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no SNP infusion)
Number of subjects: 120
Study: 10150723

Group type: EXPERIMENTAL
Intervention: In-depth training on the middle school tobacco prevention curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 2687645

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg i.m. every 3 weeks for 12 months + oral calcium supplement (1 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + oral calcium supplement (1 g/day)
Number of subjects: 20
Study: 130058

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 298
Study: 31778478

Group type: EXPERIMENTAL
Intervention: Kaolin treatment (T1): Immature or newly emerged adults of P. solenopsis sprayed with kaolin and fed with cotton leaf discs treated with kaolin suspension.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water treatment (T2): Immature or newly emerged adults of P. solenopsis sprayed with distilled water and fed with cotton leaf discs treated with distilled water.
Number of subjects: 0
Study: 31374033

Group type: EXPERIMENTAL
Intervention: 317-nursing mobile application program (317NAPP)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Telephonic consultations (control)
Number of subjects: 127
Study: 25985405

Group type: EXPERIMENTAL
Intervention: Mother (triple regimen)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Infant (nevirapine)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Neither (no prophylaxis)
Number of subjects: 2369
Study: 23962449

Group type: EXPERIMENTAL
Intervention: gemcitabine/vinorelbine (GEMVIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cisplatin/gemcitabine (PG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cisplatin/vinorelbine (PV)
Number of subjects: 0
Study: 21293451

Group type: EXPERIMENTAL
Intervention: 10-mg CP-945,598
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: 20-mg CP-945,598
Number of subjects: 3750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: Combination of lifestyle and CP-945,598
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: CP-945,598
Number of subjects: 3750
Study: 19218298

Group type: EXPERIMENTAL
Intervention: Isokinetic exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 40
Study: 18603988

Group type: EXPERIMENTAL
Intervention: Percutaneous thread loop
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-loop group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 15070094

Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the stomach
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the proximal small bowel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the distal small bowel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 mg lumiracoxib via site-specific radiolabeled delivery capsule to the ascending colon
Number of subjects: 11
Study: 11704128

Group type: EXPERIMENTAL
Intervention: G1.2/G2.2 media
Number of subjects: 249

Group type: COMPARATOR
Intervention: Sydney IVF media
Number of subjects: 249
Study: 9385564

Group type: EXPERIMENTAL
Intervention: RO 47‐0203, 30 mg/kg orally per day, two single doses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study: 8201835

Group type: EXPERIMENTAL
Intervention: C2 (rifampicin 40 mg/kg and 1200 mg clofazimine once)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: C4 (rifampicin 40 mg/kg, clofazimine 100 mg, DDS 100 mg and ethionamide 500 mg once)
Number of subjects: 622

Group type: COMPARATOR
Intervention: C2 and C4 (combined)
Number of subjects: 622
Study: 2838442

Group type: EXPERIMENTAL
Intervention: Neutron boost irradiation (dose levels: 3.6, 4.2, 4.8, 5.2, 5.6, 6.0 Gyn gamma) along with whole brain photon irradiation (1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Historical photon controls
Number of subjects: 190
Study: 31197990

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA) assisted by mesh locator
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional method of PFNA implantation
Number of subjects: 94
Study: 28322476

Group type: EXPERIMENTAL
Intervention: Intensified treatment with more frequent sessions in a shorter period of time
Number of subjects: 700

Group type: COMPARATOR
Intervention: Distributed sessions over longer time intervals
Number of subjects: 700
Study: 26742305

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC) plus placebo for leflunomide (LEF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Leflunomide (LEF) plus XFC placebo
Number of subjects: 45
Study: 23131133

Group type: EXPERIMENTAL
Intervention: Air abrasion with 50‐μm aluminum oxide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (CoJet)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 80
Study: 21212367

Group type: EXPERIMENTAL
Intervention: Iopamidol (370 mg of iodine per milliliter, n = 63)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Iodixanol (320 mg of iodine per milliliter, n = 67)
Number of subjects: 130
Study: 18078537

Group type: EXPERIMENTAL
Intervention: Risperidone (2‐6 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Haloperidol (2‐40 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol (both groups)
Number of subjects: 28
Study: 17538084

Group type: EXPERIMENTAL
Intervention: Early surgery (microdiskectomy)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Conservative treatment with eventual surgery if needed
Number of subjects: 283
Study: 15138461

Group type: EXPERIMENTAL
Intervention: Arginine-enhanced formula with arginine and fiber (group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous formula with fiber (group II)
Number of subjects: 90
Study: 11989571

Group type: EXPERIMENTAL
Intervention: Fluvastatin plus diet
Number of subjects: 19
Study: 9219205

Group type: EXPERIMENTAL
Intervention: Incremental cycle ergometer test at 50, 70, or 90 rpm
Number of subjects: 40
Study: 8191901

Group type: EXPERIMENTAL
Intervention: Exercise at 75% VO2max for 40 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Exercise at 70-75% VO2max for 40 min after timolol ingestion
Number of subjects: 6
Study: 3307976

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31540737

Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal (CoM)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Metal-on-metal (MoM)
Number of subjects: 211
Study: 30535555

Group type: EXPERIMENTAL
Intervention: Erector Spinae Block (ESB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tumescent Anesthesia
Number of subjects: 44
Study: 28583757

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg at 6-hour intervals)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal saline (placebo at 6-hour intervals)
Number of subjects: 67
Study: 26757748

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX; anti‐CD20) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 25178882

Group type: EXPERIMENTAL
Intervention: L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: L. salivarius TI 2711
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans)
Number of subjects: 64

Group type: COMPARATOR
Intervention: xylitol
Number of subjects: 64
Study: 22840410

Group type: EXPERIMENTAL
Intervention: Microsuturing with 1 or 2 6/0 vicryl suture (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 19622684

Group type: EXPERIMENTAL
Intervention: 17.5 mg hydrocortisone (HCORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17486686

Group type: EXPERIMENTAL
Intervention: Fixed valerian hops extract combination (Ze 91019)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single valerian extract (Ze 911)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15114701

Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 500 mg/day gefitinib
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Symptom improvement
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 102
Study: 11574339

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 66
Study: 9595978

Group type: EXPERIMENTAL
Intervention: Multiple, isolated U-fiber lesions
Number of subjects: 53

Group type: COMPARATOR
Intervention: No U-fiber lesions or only a single U-fiber lesion
Number of subjects: 53
Study: 8151002

Group type: EXPERIMENTAL
Intervention: Nicotine skin patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no nicotine patch)
Number of subjects: 0
Study: 3130371

Group type: EXPERIMENTAL
Intervention: Ventilatory muscle training (isocapnic hyperpnea) for 30 min/day, 4 days/wk for 8 wk
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 30711905

Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (PTT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treadmill training (CTT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overground gait analysis at T8
Number of subjects: 38
Study: 28661816

Group type: EXPERIMENTAL
Intervention: Outreach messages emphasizing dental benefits
Number of subjects: 32993

Group type: COMPARATOR
Intervention: Outreach messages emphasizing health benefits
Number of subjects: 32993
Study: 25528078

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (increase intake of fruits and vegetables, reduce red and processed meats) via telephone and printed materials
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 93
Study: 23791456

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy for depression
Number of subjects: 105

Group type: COMPARATOR
Intervention: Brief psychoeducational intervention
Number of subjects: 105
Study: 21777954

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel with 20 mg esomeprazole
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel with 150 mg ranitidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 21
Study: 20183542

Group type: EXPERIMENTAL
Intervention: Cold video
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pain video
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Itchiness video
Number of subjects: 3
Study: 17596252

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 100
Study: 15249570

Group type: EXPERIMENTAL
Intervention: GHRH (1 mg subcutaneously twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10650325

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/d orally)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 80
Study: 9094066

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid from GBS patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cerebrospinal fluid from CIDP patients
Number of subjects: 2
Study: 8477064

Group type: EXPERIMENTAL
Intervention: MEVP therapy (10 mg/m2 of mitoxantrone intravenously on day 1, 2 mg/m2 of vindesine intravenously on day 1, 200 mg/m2 of etoposide orally on days 1-3, and 40 mg/m2 of prednisolone orally on days 1-5, repeated every 3 weeks for up to 10 courses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: CHOP therapy
Number of subjects: 57
Study: 3513808

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (Conventional diuretic treatment)
Number of subjects: 16
Study: 29706129

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 200

Group type: COMPARATOR
Intervention: No cilostazol (Control)
Number of subjects: 200
Study: 27528101

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) monotherapy
Number of subjects: 322
Study: 24509936

Group type: EXPERIMENTAL
Intervention: Televised testimonials from rheumatologists and allied health professionals in the waiting room
Number of subjects: 2908

Group type: COMPARATOR
Intervention: No TV (control group)
Number of subjects: 2908
Study: 21946836

Group type: EXPERIMENTAL
Intervention: Infant formula with polydextrose (PDX) and galacto-oligosaccharides (GOS) (4 g/L, 1:1 ratio)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Infant formula with PDX/GOS
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control (Enfamil Lipil)
Number of subjects: 230
Study: 19574065

Group type: EXPERIMENTAL
Intervention: Perpendicular plating (group I)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Parallel plating (group II)
Number of subjects: 35
Study: 18422771

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen patches (Fem7, 100 microg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone agonist therapy
Number of subjects: 14
Study: 15969877

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 12766246

Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 10
Study: 10845571

Group type: EXPERIMENTAL
Intervention: 1628G‐‐>A (R485K) polymorphism of factor V
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 316
Study: 8813896

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides 5 g/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides 15 g/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (both doses)
Number of subjects: 24
Study: 1553890

Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg once/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3890587

Group type: EXPERIMENTAL
Intervention: Lofexidine (0.4 mg orally every 6 hours for 48 hours)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 63
Study: 31836201

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)
Number of subjects: 104
Study: 26936232

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily for 12 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily
Number of subjects: 34
Study: 26850901

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 239
Study: 24517110

Group type: EXPERIMENTAL
Intervention: Clinician and caregiver feedback intervention (INT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Attention control group (CON)
Number of subjects: 300
Study: 22821644

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day (Tel80)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Telmisartan 40 mg + Amlodipine 5 mg (Tel40 + Aml5)
Number of subjects: 40
Study: 20679277

Group type: EXPERIMENTAL
Intervention: Women's crisis house (randomised arm)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional psychiatric wards (randomised arm)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Women's crisis house (patient-preference arm)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional psychiatric wards (patient-preference arm)
Number of subjects: 41
Study: 18073543

Group type: EXPERIMENTAL
Intervention: 5 ml/kg 20% mannitol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3% hypertonic saline (HS)
Number of subjects: 40
Study: 15710659

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11343005

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (HT) plus usual care
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Community-based monitoring (CBM) plus usual care
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 26
Study: 9273829

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (0.56 g of alcohol per kg of body weight)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placebo beverage (3 mL of alcohol)
Number of subjects: 35
Study: 7892777

Group type: EXPERIMENTAL
Intervention: Children in the clinical group (patients at a child and adolescent psychiatric clinic)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (children without psychiatric issues)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Parents' mental health and children's behavioral disturbances
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Parents' social networks and children's behavioral disturbances
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Parents' mental health and their social networks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Parents' mental health and children's social networks
Number of subjects: 39
Study: 3223489

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (self-help manual, televised broadcast, weekly support meetings, supportive phone calls)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 100000
Study: 2277739

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol and systemic corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhaled albuterol and placebo
Number of subjects: 50
Study: 54634

Group type: EXPERIMENTAL
Intervention: Cysteamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no cysteamine)
Number of subjects: 38
Study: 30318664

Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure (Exposure)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 61
Study: 28303470

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (2.5 g/day)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Polyol chewing gum
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 179
Study: 25566827

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention including HH products, training sessions, and posters/stickers
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 545
Study: 22732766

Group type: EXPERIMENTAL
Intervention: Vardenafil (20, 10 or 5 mg single oral doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vardenafil co-medicated with bosentan
Number of subjects: 16
Study: 21310291

Group type: EXPERIMENTAL
Intervention: Intervention (trained family planning counselors)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 906
Study: 19247776

Group type: EXPERIMENTAL
Intervention: Brief lecture on anesthesia covering seven intervention questions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control questions (seven questions not covered in the lecture)
Number of subjects: 50
Study: 16759047

Group type: EXPERIMENTAL
Intervention: Immediate enfuvirtide/optimized‐background treatment regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 16‐week treatment interruption followed by enfuvirtide/optimized‐background treatment regimen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline phenotypic susceptibility score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enfuvirtide‐containing regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment interruption
Number of subjects: 30
Study: 15374792

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 7179

Group type: COMPARATOR
Intervention: Non-black patients
Number of subjects: 7179
Study: 11699489

Group type: EXPERIMENTAL
Intervention: HTR (microporous biocompatible composite of PMMA, PHEMA and calcium hydroxide graft)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ePTFE (expanded polytetrafluoroethylene barrier membrane)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of HTR and ePTFE
Number of subjects: 8

Group type: COMPARATOR
Intervention: HTR alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: ePTFE alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 8
Study: 9155807

Group type: EXPERIMENTAL
Intervention: Interplak electric toothbrush
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Philips electric toothbrush
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rotadent electric toothbrush
Number of subjects: 36

Group type: COMPARATOR
Intervention: Manual multitufted toothbrush (Blend‐a‐Med)
Number of subjects: 36